RedHill Could Soon Seek EUA For COVID-19 Therapy
Opaganib Shows Promise In Severe Sufferers
Executive Summary
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
You may also be interested in...
Coronavirus Update: RedHill’s Opaganib Fails As Company Accelerates RHB-107 Study
The Israeli biotech announced disappointing Phase II/III data for opaganib while expanding its Phase II/III RHB-107 study. Pharming unveiled promising data from a company-sponsored study, but an imbalance in an investigator-led study confounded results, while CalciMedica built on the case for its drug as a treatment for COVID-19 pneumonia.
Coronavirus Update: Veklury Shows Mortality Benefit In Real-World Data Analyses
Sotrovimab data could help with uptake, though the market remains challenging as infections fall. Plus RedHill presents encouraging Phase II data for oral drug to treat COVID-19 infection and inflammation after completing Phase II/III study enrollment and Japan taps its world-leading supercomputer.
ObvioHealth Is Building A New Digital Ecosystem To 'Revolutionize' Trials
Using artificial intelligence and strict data collection protocol, ObvioHealth hopes to digitize clinical trials with the assistance of medical devices and consumer technology.